Efficacy of conventional immunosuppressive therapy in related and unrelated living renal transplantation

Clinical Transplantation

Volumn 20, Issue 3, 2006, Pages 284-288

  Thorban, Stefan ^a   Schwarznau, A ^a   Huser N ^a   Stangl, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Immunosuppression; Induction therapy; Living related renal transplantation

Indexed keywords

CORTICOSTEROID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HEALTH CARE FACILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

ADULT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745114444     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00479.x     Document Type: Article

References (30)

1. Wolters HH, Heidenreich S, Dame C, Brockmann JG, Senninger N, Krieglstein CF. Living donor kidney transplantation: Impact of differentiated immunosuppressive regimen. Transplant Proc 2005: 37: 1616.
2. Wiland AM, Fink JC, Weir MR et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004: 77: 422.
3. Campbell SB, Hothersall E, Preston J et al. Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. Transplantation 2003: 76: 1452.
4. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001: 72: 1915.
5. Knight RJ, Kerman RH, Schoenberg L et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2005: 79: 991.
6. Fuller TF, Feng S, Brennan TV, Tomlanovich S, Bostrom A, Freise CE. Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Transplantation 2004: 78: 1030.
7. Matas AJ, Gillingham KJ, Humar A, Dunn DL, Sutherland DE, Najarian JS. Immunologic and nonimmunologic factors: Different risks for cadaver and living donor transplantation. Transplantation 2000: 69: 54.
8. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998: 128: 817.
9. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997: 350: 1484.
10. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003: 76: 798.
11. Haririan A, Morawski K, Sillix DH et al. Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 2005: 79: 716.
12. Haririan A, Morawski K, Garnick J, et al. The results of thymoglobin vs basiliximab induction in African-American renal allograft recipients. Third International Congress on Immunosuppression, poster No. 28, abstract band S. 123, San Diego, USA, 2004.
13. Hardinger KL, Schnitzler MA, Miller B et al. Five years follow-up of thymoglobin versus ATGAM induction in adult renal transplantation. Transplantation 2004: 78: 136.
14. Brennan DC, Flavin K, Lowell JA et al. A randomized double-blinded comparison of thymoglobin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999: 67: 1011.
15. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobin or campath. J Am Coll Surg 2005: 4: 505.
16. Trofe J, Stratta RJ, Egidi MF et al. Thymoglobin for induction or rejection therapy in pancreas allograft recipients: A single center experience. Clin Transplant 2002: 16: 34.
17. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobin in adult cadaveric renal transplant recipients. Transplantation 2003: 76: 839.
18. Baron PW, Weissman J, Ojogho ON et al. Use of basiliximab with mycophenolate mofetil in kidney transplantation. Transplant Proc 2003: 38: 2881.
19. Chapman TM, Keating GM. Basiliximab: A review of its use as induction therapy in renal transplantation. Drugs 2003: 63: 2803.
20. Pascual M, Theruvath T, Kawai T et al. Strategies to improve longterm outcomes after renal transplantation. N Engl J Med 2002: 346: 580.
21. Varenterghem Y, Lebranchu Y, Hene R et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000: 70: 1352.
22. Vicenti F. Immunosuppression minimalization: Current and future trends in transplant immunosuppression. J Am Soc Nephrol 2003: 14: 1940.
23. Pascual J, Quereda C, Zamora J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: A meta-analysis of randomized, controlled trials. Transplantation 2004: 17: 1548.
24. Roastaing L, Cantarovich D, Mourad G et al. CARMEN Study Group: corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005: 79: 807.
25. Borrows R, Loucaidou M, Van Tromp J et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004: 4: 1845.
26. Wright F, Ortiz J, Varma C, Shaugnessy P. Campath-1H Induction in live and deceased donor renal transplantation allows reduced dose maintenance therapy and steroid avoidance. Third International Congress on Immunosuppression, San Diego, USA, abstract No. 92, abstractband S. 72, 2004.
27. Hricik DE. Steroid withdrawal for the (selected) masses. Am J Transplant 2005: 5: 639.
28. Hricik DE, Knauss TC, Bodziak KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003: 76: 938.
29. Schulak JA. Steroid immunosuppression in kidney transplantation: A passing era. J Surg Res 2004: 117: 154.
30. Woodle ES TRIMS Study Group. A randomized, prospective, multicenter study of thymoglobin in renal transplantation for induction and minimalization of steroids (TRIMS). Am J Transplant 2005: 5 (Suppl. 11): 571.